Asymchem Laboratories (Tianjin) (002821) Fundamentals 2026 — P/E 52.8x, Revenue Analysis | SniperIQ
Asymchem Laboratories (Tianjin) (002821) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥54.7B, trading at ¥164.28 on the SHZ. This SniperIQ fundamentals page covers Asymchem Laboratories (Tianjin)'s valuation (P/E 52.8x, P/B 3.3x), profitability (net margin 16.0%), revenue (¥6.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Asymchem Laboratories (Tianjin)'s market cap?
Asymchem Laboratories (Tianjin) (002821) has a market capitalization of approximately ¥54.7B, trading at ¥164.28 on the SHZ. Market cap moves with the live share price.
What is Asymchem Laboratories (Tianjin)'s P/E ratio?
Asymchem Laboratories (Tianjin)'s trailing twelve-month P/E ratio is 52.8x, with a price-to-book (P/B) of 3.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Asymchem Laboratories (Tianjin)?
Asymchem Laboratories (Tianjin) runs a net profit margin of 16.0%, a gross margin of 42.0%, and an operating margin of 24.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Asymchem Laboratories (Tianjin) generate?
Asymchem Laboratories (Tianjin) reported revenue of ¥6.7B for fiscal year 2025, with net income of ¥1.1B and earnings per share (EPS) of 3.16. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Asymchem Laboratories (Tianjin) pay a dividend?
Asymchem Laboratories (Tianjin) offers a trailing dividend yield of about 0.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Asymchem Laboratories (Tianjin) financially healthy?
Asymchem Laboratories (Tianjin) carries a debt-to-equity ratio of 0.01x and a current ratio of 5.69x, with a market beta of 0.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Asymchem Laboratories (Tianjin) a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Asymchem Laboratories (Tianjin) (002821) the key facts are: market cap ¥54.7B, P/E 52.8x, revenue ¥6.7B, 52-week range 88.46-200. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Asymchem Laboratories (Tianjin)'s full fundamentals live
Get Asymchem Laboratories (Tianjin)'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.